Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102973 · ClinicalTrials.gov registry record · Phase 3
TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
A Phase 3 study, sponsored by Telik.
- Completed
- Registry status
- Phase 3
- Development phase
- 244
- Enrollment target
NCT00102973 is a Phase 3 study that has completed, run by Telik. The registered enrollment target is 244 participants.
The verdict
NCT00102973, a Phase 3 study, has completed, sponsored by Telik.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 244 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to platinum chemotherapy.
Interventions
- DRUG TLK286 in Combination with Carboplatin
- DRUG Doxorubicin HCl Liposome Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2004-12 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102973
The ClinicalTrials.gov registry entry for NCT00102973 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telik, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TLK286 in Combination with Carboplatin is the first listed.
NCT00102973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00102973 about?
NCT00102973 is a clinical study titled "TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer". The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to plat...
What is the current status of trial NCT00102973?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 244 participants. The study started on 2004-12. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00102973?
The interventions under investigation include: TLK286 in Combination with Carboplatin (DRUG), Doxorubicin HCl Liposome Injection (DRUG).
Who is sponsoring clinical trial NCT00102973?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.